ABVX Stock: Price, Earnings History and SEC Filings
ABIVAX Société Anonyme (ABVX) last traded at $86.59, down 2.77% on the latest session and down 12.6% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-1.71 against an analyst estimate of $-1.08, a miss of 58.3%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ABVX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Sep 21, 2026 | $-1.71 | $-1.08 | -58.33% |
| Mar 2026 | May 22, 2026 | $-0.71 | $-1.07 | +33.64% |
| Dec 2025 | Mar 23, 2026 | $-1.19 | $-1.70 | +30.00% |
ABVX beat the analyst EPS estimate in 2 of its last 3 reported quarters. Source: Nasdaq.
Latest SEC filings for ABVX
Insider filing activity
ABVX insiders filed 0 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
ABVX news
- Abivax SA Sponsored ADROct 21, 2026 · cnn.com
- Piper Sandler on Abivax (ABVX): 'Obefazimod's Differentiated Profile Reinforced by UEGW Data'Oct 21, 2026 · streetinsider.com
About ABIVAX Société Anonyme
ABIVAX Société Anonyme (ABVX) is a US-listed public company on Nasdaq. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in France. Its fiscal year ends in December.